Abstract
Immune checkpoint blockade is one of the central pillars of therapy for metastatic melanoma. Recently, cell cycle inhibitors such as palbociclib have demonstrated antitumor activity in vivo in different tumour entities. Besides tumour cell killing, tumour therapy also induces senescence, which is characterized by a stable growth arrest. The secretome of senescent cells, termed senescence- associated secretory phenotype (SASP), has diverse effects on tumor growth. We wondered how the SASP of therapy-induced senescent (TIS) cells differs from the SASP of cytokine-induced senescent (CIS) cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
